Int J Gynaecol Obstet. 2021 Oct 6. doi: 10.1002/ijgo.13969. Online ahead of print.
ABSTRACT
OBJECTIVE: To investigate the effect of ramosetron after gynecological laparoscopic surgery on the recovery of bowel function.
METHODS: A prospective randomized controlled trial conducted at Kyung Hee University hospital, South Korea, from August 2016 to September 2017. Patients were randomized to receive either 10 mg dexamethasone before induction of anesthesia (control group C), followed by intravenous administration of patient-controlled analgesia (IV-PCA) or 2 mL normal saline before induction of anesthesia and 0.6 mg ramosetron (study group R) administered with IV-PCA.
RESULTS: A total of 88 patients were enrolled. Times to first flatus (group C 23.98 ± 6.31 vs group R 27.14 ± 9.56 hours; P = 0.148) and first defecation (group C 36.16 ± 16.04 vs group R 43.41 ± 20.01 hours; P = 0.138) showed no statistically significant differences. No significant differences were observed in the frequency of postoperative nausea and vomiting (PONV) and demand for additional analgesics. Multiple linear regression for analysis of factors affecting time to first flatus revealed no significant results.
CONCLUSION: Ramosetron did not delay bowel movement recovery after gynecologic laparoscopic surgery and was as effective as dexamethasone in regulating PONV. Ramosetron can be used with IV-PCA without concerns about delay in recovery of bowel function.
PMID:34614204 | DOI:10.1002/ijgo.13969
